Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Insider: Allakos, Live Nation among week's notable insider transactions » 15:10
09/26/22
09/26
15:10
09/26/22
15:10
NLOK

NortonLifeLock

$20.57 /

-0.11 (-0.53%)

, ADBE

Adobe

$279.61 /

-4.8 (-1.69%)

, NAUT

Nautilus Biotechnology

$1.97 /

-0.025 (-1.25%)

, ALLK

Allakos

$5.79 /

+0.545 (+10.39%)

, LYV

Live Nation

$74.14 /

-1.17 (-1.55%)

, CRWD

Crowdstrike

$161.25 /

+1.02 (+0.64%)

, AN

AutoNation

$105.98 /

-0.98 (-0.92%)

, AMRS

Amyris

$3.04 /

+0.005 (+0.16%)

Welcome to "Fly Insider,"…

ShowHide Related Items >><<
NLOK NortonLifeLock
$20.57 /

-0.11 (-0.53%)

NAUT Nautilus Biotechnology
$1.97 /

-0.025 (-1.25%)

LYV Live Nation
$74.14 /

-1.17 (-1.55%)

CRWD Crowdstrike
$161.25 /

+1.02 (+0.64%)

AN AutoNation
$105.98 /

-0.98 (-0.92%)

AMRS Amyris
$3.04 /

+0.005 (+0.16%)

ALLK Allakos
$5.79 /

+0.545 (+10.39%)

ADBE Adobe
$279.61 /

-4.8 (-1.69%)

NLOK NortonLifeLock
$20.57 /

-0.11 (-0.53%)

05/09/22 Baird
NortonLifeLock price target lowered to $28 from $31 at Baird
03/29/22 Morgan Stanley
NortonLifeLock downgraded to Equal Weight from Overweight at Morgan Stanley
ADBE Adobe
$279.61 /

-4.8 (-1.69%)

09/22/22 MoffettNathanson
Adobe initiated with a Hold at MoffettNathanson
09/19/22 Wells Fargo
Wells Fargo downgrades Adobe to Equal Weight, lowers price target to $310
09/19/22 Edward Jones
Adobe downgraded to Hold from Buy at Edward Jones
09/19/22 Wells Fargo
Adobe downgraded to Equal Weight from Overweight at Wells Fargo
NAUT Nautilus Biotechnology
$1.97 /

-0.025 (-1.25%)

01/06/22 Morgan Stanley
Nautilus Biotechnology initiated with an Equal Weight at Morgan Stanley
11/02/21 Cowen
Cowen starts Nautilus Biotechnology with Outperform, Proteomics potential seen
11/02/21 Cowen
Nautilus Biotechnology initiated with an Outperform at Cowen
ALLK Allakos
$5.79 /

+0.545 (+10.39%)

09/12/22 Cantor Fitzgerald
Allakos price target lowered to $7 from $10 at Cantor Fitzgerald
09/12/22 SMBC Nikko
Allakos downgraded to Underperform from Neutral at SMBC Nikko
08/08/22 BofA
Allakos price target lowered to $4 from $5 at BofA
05/11/22 Barclays
Allakos price target lowered to $2.50 from $7 at Barclays
LYV Live Nation
$74.14 /

-1.17 (-1.55%)

08/08/22 Credit Suisse
Liberty SiriusXM price target lowered to $52 from $64 at Credit Suisse
08/08/22 Citi
Live Nation price target raised to $100 from $93 at Citi
07/07/22 Citi
Live Nation price target lowered to $93 from $96 at Citi
07/05/22 Macquarie
Live Nation upgraded to Outperform at Macquarie with shares down 35% from peak
CRWD Crowdstrike
$161.25 /

+1.02 (+0.64%)

09/22/22 MoffettNathanson
Crowdstrike initiated with a Buy at MoffettNathanson
09/21/22 BTIG
BTIG more confident in Crowdstrike growth potential
09/16/22 MKM Partners
MKM Partners starts Crowdstrike at Buy with $240 price target
09/15/22 MKM Partners
Crowdstrike initiated with a Buy at MKM Partners
AN AutoNation
$105.98 /

-0.98 (-0.92%)

09/09/22 BofA
AutoNation price target lowered to $238 from $250 at BofA
08/23/22 Argus
Argus starts AutoNation at Buy, sees technology boosting sales and margins
08/23/22 Argus
AutoNation initiated with a Buy at Argus
07/25/22 Seaport Global
AutoNation upgraded to Buy from Neutral at Seaport Global
AMRS Amyris
$3.04 /

+0.005 (+0.16%)

09/19/22 Piper Sandler
Amyris price target raised to $4 from $2.50 at Piper Sandler
08/10/22 Roth Capital
Roth Capital downgrades Amyris to Neutral, lowers price target to $2
08/10/22 Roth Capital
Amyris downgraded to Neutral from Buy at Roth Capital
06/24/22 JPMorgan
Amyris initiated with a Neutral at JPMorgan
NLOK NortonLifeLock
$20.57 /

-0.11 (-0.53%)

NAUT Nautilus Biotechnology
$1.97 /

-0.025 (-1.25%)

LYV Live Nation
$74.14 /

-1.17 (-1.55%)

CRWD Crowdstrike
$161.25 /

+1.02 (+0.64%)

AN AutoNation
$105.98 /

-0.98 (-0.92%)

AMRS Amyris
$3.04 /

+0.005 (+0.16%)

ALLK Allakos
$5.79 /

+0.545 (+10.39%)

ADBE Adobe
$279.61 /

-4.8 (-1.69%)

  • 19
    Sep
NLOK NortonLifeLock
$20.57 /

-0.11 (-0.53%)

LYV Live Nation
$74.14 /

-1.17 (-1.55%)

CRWD Crowdstrike
$161.25 /

+1.02 (+0.64%)

ADBE Adobe
$279.61 /

-4.8 (-1.69%)

NLOK NortonLifeLock
$20.57 /

-0.11 (-0.53%)

LYV Live Nation
$74.14 /

-1.17 (-1.55%)

CRWD Crowdstrike
$161.25 /

+1.02 (+0.64%)

AN AutoNation
$105.98 /

-0.98 (-0.92%)

AMRS Amyris
$3.04 /

+0.005 (+0.16%)

ADBE Adobe
$279.61 /

-4.8 (-1.69%)

NLOK NortonLifeLock
$20.57 /

-0.11 (-0.53%)

LYV Live Nation
$74.14 /

-1.17 (-1.55%)

CRWD Crowdstrike
$161.25 /

+1.02 (+0.64%)

AMRS Amyris
$3.04 /

+0.005 (+0.16%)

ADBE Adobe
$279.61 /

-4.8 (-1.69%)

Over a week ago
Recommendations
Amyris price target raised to $4 from $2.50 at Piper Sandler » 06:17
09/19/22
09/19
06:17
09/19/22
06:17
AMRS

Amyris

$3.54 /

-0.24 (-6.35%)

Piper Sandler analyst…

Piper Sandler analyst Korinne Wolfmeyer raised the firm's price target on Amyris to $4 from $2.50 and keeps a Neutral rating on the shares. Management noted that August posted the strongest consumer month on record for the company, and Q3 is on track to be the strongest consumer quarter yet, Wolfmeyer tells investors in a research note. The analyst is a fan of management's Fit to Win Program.

ShowHide Related Items >><<
AMRS Amyris
$3.54 /

-0.24 (-6.35%)

AMRS Amyris
$3.54 /

-0.24 (-6.35%)

08/10/22 Roth Capital
Roth Capital downgrades Amyris to Neutral, lowers price target to $2
08/10/22 Roth Capital
Amyris downgraded to Neutral from Buy at Roth Capital
06/24/22 JPMorgan
Amyris initiated with a Neutral at JPMorgan
05/25/22 Piper Sandler
Amyris initiated with a Neutral at Piper Sandler
AMRS Amyris
$3.54 /

-0.24 (-6.35%)

AMRS Amyris
$3.54 /

-0.24 (-6.35%)

AMRS Amyris
$3.54 /

-0.24 (-6.35%)

Hot Stocks
Amyris names Elizabeth Dreyer as Chief Accounting Officer » 09:08
09/14/22
09/14
09:08
09/14/22
09:08
AMRS

Amyris

$4.05 /

+0.145 (+3.71%)

In a regulatory 8-K…

In a regulatory 8-K filing, the company states: "On September 9, 2022, Elizabeth Dreyer agreed to join Amyris, Inc. as its Chief Accounting Officer & Corporate Controller, reporting to Han Kieftenbeld, the Company's Chief Financial Officer, effective October 11, 2022. Ms. Dreyer has over 20 years of U.S. public company accounting experience with more than 10 years of experience as Chief Accounting Officer of public companies. Most recently, she served as Chief Accounting Officer of Travel + Leisure Co., a publicly-traded global provider of hospitality services and travel products and Wyndham spin-off, from June 2018 until September 2022, after joining Wyndham Worldwide Corp. in March 2018. Previously, Ms. Dreyer served as Vice President, Controller and Chief Accounting Officer of Edgewell Personal Care Company, a manufacturer and marketer of consumer products, from January 2015 to March 2018."

ShowHide Related Items >><<
AMRS Amyris
$4.05 /

+0.145 (+3.71%)

AMRS Amyris
$4.05 /

+0.145 (+3.71%)

08/10/22 Roth Capital
Roth Capital downgrades Amyris to Neutral, lowers price target to $2
08/10/22 Roth Capital
Amyris downgraded to Neutral from Buy at Roth Capital
06/24/22 JPMorgan
Amyris initiated with a Neutral at JPMorgan
05/25/22 Piper Sandler
Amyris initiated with a Neutral at Piper Sandler
AMRS Amyris
$4.05 /

+0.145 (+3.71%)

AMRS Amyris
$4.05 /

+0.145 (+3.71%)

AMRS Amyris
$4.05 /

+0.145 (+3.71%)

Hot Stocks
Director of Akoya Biosciences Nolan sells $319K in company shares » 17:00
09/13/22
09/13
17:00
09/13/22
17:00
AKYA

Akoya Biosciences

$12.67 /

-0.32 (-2.46%)

Director of Akoya…

Director of Akoya Biosciences Garry Nolan disclosed in a regulatory filing that he had sold 23,991 shares of company stock at $13.31 per share between September 9 and September 12, for a total transaction amount of $319,282.

ShowHide Related Items >><<
AKYA Akoya Biosciences
$12.67 /

-0.32 (-2.46%)

AKYA Akoya Biosciences
$12.67 /

-0.32 (-2.46%)

08/17/22 Piper Sandler
Akoya Biosciences price target raised to $17 from $14 at Piper Sandler
06/22/22 BTIG
Akoya Biosciences initiated with a Buy at BTIG
05/15/22 Piper Sandler
Akoya Biosciences price target lowered to $14 from $18 at Piper Sandler
04/13/22 Piper Sandler
Akoya not impacted from NanoString miss, says Piper Sandler
AKYA Akoya Biosciences
$12.67 /

-0.32 (-2.46%)

Hot Stocks
Exact Sciences announces data from MCED biomaker validation study » 13:06
09/10/22
09/10
13:06
09/10/22
13:06
EXAS

Exact Sciences

$40.66 /

+1.73 (+4.44%)

Exact Sciences announced…

Exact Sciences announced data from a multi-cancer early detection, or MCED, biomarker validation study was presented at the European Society for Medical Oncology Congress. The study rigorously assessed the performance of four distinct biomarker classes found in the blood and known to signal the presence of cancer regardless of its location in the body. Four biomarker classes, discovered through years of collaboration with Johns Hopkins and Mayo Clinic and analyzed together for the first time in this study, demonstrated the ability to detect cancer signal from 15 organ sites with a mean sensitivity of 61% and mean specificity of 98.2%. The multi-biomarker approach, including aneuploidy, proteins, and DNA methylation and mutations, provided encouraging cancer detection in stages I and II, with a combined sensitivity of 38.7%. The retrospective, case-control study included cancers from 11 organ sites with no recommended screening option today and 15 organ sites and tissue in total, including breast, bladder, colon, esophageal, kidney, liver, lung, multiple myeloma, myelodysplastic syndrome, non-Hodgkin's lymphoma, ovarian, pancreatic, prostate, stomach, and uterine. The non-cancer control cohort included age-matched, presumably healthy individuals and samples from individuals with non-cancer diseases to represent the intended use population more effectively. A larger case-control study is underway to further validate the results shared at ESMO and determine the final design of the MCED test. Exact Sciences will then begin recruiting patients for the FDA registrational Study Of All comeRs trial in MCED during 2023. The SOAR trial will be the largest prospective, interventional MCED trial ever conducted in the United States. Exact Sciences plans to leverage its leading presence in primary care and cancer screening to accelerate the availability of MCED and deliver this powerful innovation to patients in need.

ShowHide Related Items >><<
EXAS Exact Sciences
$40.66 /

+1.73 (+4.44%)

EXAS Exact Sciences
$40.66 /

+1.73 (+4.44%)

08/24/22 Credit Suisse
Exact Sciences initiated with an Outperform at Credit Suisse
08/17/22 Piper Sandler
Exact Sciences price target lowered to $40 from $50 at Piper Sandler
08/03/22 Craig-Hallum
Exact Sciences price target lowered to $60 from $81 at Craig-Hallum
08/03/22 Cowen
Exact Sciences price target lowered to $67 from $83 at Cowen
EXAS Exact Sciences
$40.66 /

+1.73 (+4.44%)

EXAS Exact Sciences
$40.66 /

+1.73 (+4.44%)

Hot Stocks
Cathie Wood's ARK Investment bought 188K shares of Exact Sciences today  20:05
09/06/22
09/06
20:05
09/06/22
20:05
EXAS

Exact Sciences

$35.39 /

-0.72 (-1.99%)

 
ShowHide Related Items >><<
EXAS Exact Sciences
$35.39 /

-0.72 (-1.99%)

EXAS Exact Sciences
$35.39 /

-0.72 (-1.99%)

08/24/22 Credit Suisse
Exact Sciences initiated with an Outperform at Credit Suisse
08/17/22 Piper Sandler
Exact Sciences price target lowered to $40 from $50 at Piper Sandler
08/03/22 Craig-Hallum
Exact Sciences price target lowered to $60 from $81 at Craig-Hallum
08/03/22 Cowen
Exact Sciences price target lowered to $67 from $83 at Cowen
EXAS Exact Sciences
$35.39 /

-0.72 (-1.99%)

EXAS Exact Sciences
$35.39 /

-0.72 (-1.99%)

Over a month ago
Options
Unusually active option classes on open August 29th » 09:40
08/29/22
08/29
09:40
08/29/22
09:40
CFVI

CF Acquisition Corp. VI

$10.08 /

+ (+0.00%)

, GSAT

Globalstar

$1.99 /

+ (+0.00%)

, CCJ

Cameco

$26.65 /

+ (+0.00%)

, PDD

Pinduoduo

$57.57 /

+ (+0.00%)

, AMRS

Amyris

$3.16 /

+ (+0.00%)

, WISH

ContextLogic

$1.28 /

-0.005 (-0.39%)

, DKNG

DraftKings

$16.52 /

-0.01 (-0.06%)

, BMY

Bristol-Myers

$71.19 /

+ (+0.00%)

, BBIG

Vinco Ventures

/

+

, UUP

PowerShares DB US Dollar Index Up

$29.14 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: CF Acquisition Corp (CFVI), Globalstar (GSAT), Cameco (CCJ), Pinduoduo (PDD), Amyris (AMRS), ContextLogic (WISH), DraftKings (DKNG), Bristol Myers Squibb (BMY), Vinco Ventures (BBIG), and PowerShares DB US Dollar Index Bullish Fund (UUP).

ShowHide Related Items >><<
WISH ContextLogic
$1.28 /

-0.005 (-0.39%)

PDD Pinduoduo
$57.57 /

+ (+0.00%)

GSAT Globalstar
$1.99 /

+ (+0.00%)

DKNG DraftKings
$16.52 /

-0.01 (-0.06%)

CFVI CF Acquisition Corp. VI
$10.08 /

+ (+0.00%)

CCJ Cameco
$26.65 /

+ (+0.00%)

BMY Bristol-Myers
$71.19 /

+ (+0.00%)

BBIG Vinco Ventures
/

+

AMRS Amyris
$3.16 /

+ (+0.00%)

CFVI CF Acquisition Corp. VI
$10.08 /

+ (+0.00%)

GSAT Globalstar
$1.99 /

+ (+0.00%)

08/08/22 B. Riley
B. Riley thinks Globalstar's mystery satellite capacity customer is Apple
01/03/22 B. Riley
iStar, Aspen Aerogels among B. Riley's top 25 stock picks for 2022
12/09/21 B. Riley
B. Riley says 'excellent time' to buy Globalstar on iPhone inclusion evidence
08/30/21 William Blair
Apple may use Iridium connectivity 'down the road,' says William Blair
CCJ Cameco
$26.65 /

+ (+0.00%)

08/17/22 GLJ Research
Cameco price target raised to C$48.40 from C$37.86 at GLJ Research
08/02/22 Scotiabank
Cameco price target raised to C$44 from C$43 at Scotiabank
07/07/22 Scotiabank
Cameco price target lowered to C$43 from C$47 at Scotiabank
05/06/22 Canaccord
Cameco price target lowered to C$43 from C$44 at Canaccord
PDD Pinduoduo
$57.57 /

+ (+0.00%)

07/11/22 Goldman Sachs
Pinduoduo grocery focus to drive sustained growth, says Goldman Sachs
07/11/22 Morgan Stanley
Pinduoduo downgraded to Equal Weight from Overweight at Morgan Stanley
06/01/22 Barclays
Pinduoduo price target raised to $45 from $41 at Barclays
05/31/22 Citi
Pinduoduo price target raised to $62 from $61 at Citi
AMRS Amyris
$3.16 /

+ (+0.00%)

08/10/22 Roth Capital
Roth Capital downgrades Amyris to Neutral, lowers price target to $2
08/10/22 Roth Capital
Amyris downgraded to Neutral from Buy at Roth Capital
06/24/22 JPMorgan
Amyris initiated with a Neutral at JPMorgan
05/25/22 Piper Sandler
Amyris initiated with a Neutral at Piper Sandler
WISH ContextLogic
$1.28 /

-0.005 (-0.39%)

08/10/22 Credit Suisse
ContextLogic free cash flow to improve from here, says Credit Suisse
03/22/22 Loop Capital
ContextLogic cut to Hold at Loop Capital on inflation and and European exposure
03/22/22 Loop Capital
ContextLogic downgraded to Hold from Buy at Loop Capital
12/02/21
Fly Intel: Top five analyst downgrades
DKNG DraftKings
$16.52 /

-0.01 (-0.06%)

08/17/22 Roth Capital
Roth Capital upgrades DraftKings to Buy, raises price target to $25
08/17/22 Roth Capital
DraftKings upgraded to Buy from Neutral at Roth Capital
08/08/22 Truist
DraftKings price target raised to $20 from $16 at Truist
08/08/22 Morgan Stanley
DraftKings price target trimmed to $30 at Morgan Stanley after Q2 beat
BMY Bristol-Myers
$71.19 /

+ (+0.00%)

08/23/22 Truist
Compugen price target lowered to $4 from $14 at Truist
08/08/22 JMP Securities
Compugen price target lowered to $4 from $8 at JMP Securities
08/05/22 Truist
Global Blood could complement any oncology franchise, says Truist
08/05/22 Jefferies
Jefferies downgrades Compugen to Hold with cash likely becoming 'growing issue'
BBIG Vinco Ventures
/

+

UUP PowerShares DB US Dollar Index Up
$29.14 /

+ (+0.00%)

WISH ContextLogic
$1.28 /

-0.005 (-0.39%)

PDD Pinduoduo
$57.57 /

+ (+0.00%)

GSAT Globalstar
$1.99 /

+ (+0.00%)

DKNG DraftKings
$16.52 /

-0.01 (-0.06%)

CCJ Cameco
$26.65 /

+ (+0.00%)

BMY Bristol-Myers
$71.19 /

+ (+0.00%)

BBIG Vinco Ventures
/

+

AMRS Amyris
$3.16 /

+ (+0.00%)

PDD Pinduoduo
$57.57 /

+ (+0.00%)

DKNG DraftKings
$16.52 /

-0.01 (-0.06%)

CFVI CF Acquisition Corp. VI
$10.08 /

+ (+0.00%)

CCJ Cameco
$26.65 /

+ (+0.00%)

BMY Bristol-Myers
$71.19 /

+ (+0.00%)

WISH ContextLogic
$1.28 /

-0.005 (-0.39%)

PDD Pinduoduo
$57.57 /

+ (+0.00%)

DKNG DraftKings
$16.52 /

-0.01 (-0.06%)

CCJ Cameco
$26.65 /

+ (+0.00%)

BMY Bristol-Myers
$71.19 /

+ (+0.00%)

AMRS Amyris
$3.16 /

+ (+0.00%)

WISH ContextLogic
$1.28 /

-0.005 (-0.39%)

UUP PowerShares DB US Dollar Index Up
$29.14 /

+ (+0.00%)

PDD Pinduoduo
$57.57 /

+ (+0.00%)

GSAT Globalstar
$1.99 /

+ (+0.00%)

DKNG DraftKings
$16.52 /

-0.01 (-0.06%)

CFVI CF Acquisition Corp. VI
$10.08 /

+ (+0.00%)

CCJ Cameco
$26.65 /

+ (+0.00%)

BMY Bristol-Myers
$71.19 /

+ (+0.00%)

BBIG Vinco Ventures
/

+

AMRS Amyris
$3.16 /

+ (+0.00%)

Initiation
Exact Sciences initiated with an Outperform at Credit Suisse » 16:37
08/24/22
08/24
16:37
08/24/22
16:37
EXAS

Exact Sciences

$37.39 /

+1.39 (+3.86%)

Credit Suisse analyst Dan…

Credit Suisse analyst Dan Leonard initiated coverage of Exact Sciences with an Outperform rating and $55 price target. The company's leadership position in non-invasive colorectal cancer screening is "durable," while upcoming pipeline catalysts could "de-risk future large opportunities" like multi-cancer testing and minimal residual disease monitoring, Leonard tells investors in a research note.

ShowHide Related Items >><<
EXAS Exact Sciences
$37.39 /

+1.39 (+3.86%)

EXAS Exact Sciences
$37.39 /

+1.39 (+3.86%)

08/17/22 Piper Sandler
Exact Sciences price target lowered to $40 from $50 at Piper Sandler
08/03/22 Craig-Hallum
Exact Sciences price target lowered to $60 from $81 at Craig-Hallum
08/03/22 Cowen
Exact Sciences price target lowered to $67 from $83 at Cowen
08/03/22 BTIG
Exact Sciences price target lowered to $70 from $100 at BTIG
EXAS Exact Sciences
$37.39 /

+1.39 (+3.86%)

EXAS Exact Sciences
$37.39 /

+1.39 (+3.86%)

Syndicate
Absci files $250M mixed securities shelf  16:10
08/24/22
08/24
16:10
08/24/22
16:10
ABSI

Absci

$4.37 /

+0.11 (+2.58%)

 
ShowHide Related Items >><<
ABSI Absci
$4.37 /

+0.11 (+2.58%)

ABSI Absci
$4.37 /

+0.11 (+2.58%)

08/12/22 JPMorgan
Absci double downgraded to Underweight at JPMorgan on slower revenue ramp
08/12/22 JPMorgan
Absci downgraded to Underweight from Overweight at JPMorgan
08/12/22 Cowen
Absci upgraded to Outperform from Market Perform at Cowen
07/18/22 Truist
Truist starts Absci at Buy on confluence of biotech, next-gen biologics
ABSI Absci
$4.37 /

+0.11 (+2.58%)

ABSI Absci
$4.37 /

+0.11 (+2.58%)

Hot Stocks
Cathie Wood's ARK Investment bought 515K shares of Exact Sciences today  20:30
08/23/22
08/23
20:30
08/23/22
20:30
EXAS

Exact Sciences

$35.97 /

+0.03 (+0.08%)

 
ShowHide Related Items >><<
EXAS Exact Sciences
$35.97 /

+0.03 (+0.08%)

EXAS Exact Sciences
$35.97 /

+0.03 (+0.08%)

08/17/22 Piper Sandler
Exact Sciences price target lowered to $40 from $50 at Piper Sandler
08/03/22 Craig-Hallum
Exact Sciences price target lowered to $60 from $81 at Craig-Hallum
08/03/22 Cowen
Exact Sciences price target lowered to $67 from $83 at Cowen
08/03/22 BTIG
Exact Sciences price target lowered to $70 from $100 at BTIG
EXAS Exact Sciences
$35.97 /

+0.03 (+0.08%)

EXAS Exact Sciences
$35.97 /

+0.03 (+0.08%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.